Standard-of-care AD therapeutics such as cholinesterase inhibitors and memantine only improve cognition for a few months before patients revert to their pre-medication cognitive state, and although anti-amyloid mAbs slow cognitive decline and disease progression, they are also associated with severe adverse effects. The gene discussed is BCHE; the disease is Alzheimer disease.